Research
Hormonal
Tirzepatide consistently showed reductions in HbA1c and benefits with weight loss in clinical trials.
Tirzepatide is effective for improving glycemic control and promoting weight loss in type 2 diabetes patients.
StrongSupportsmedium confidence
Tirzepatide consistently showed reductions in HbA1c, as well as benefits with weight loss.
Why this rating
Based on pivotal phase 3 trial results.
Source
Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus
Elaine Wong et al. · American Journal of Therapeutics · 2022
DOI 10.1097/mjt.0000000000001588
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide is a first in class dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) analog approved for the management of adult patients with type 2 diabetes mellitus.Strong
- Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →